This is consistent with the trend (albeit non-significant) toward lower Hcy in both groups with non-demented DOPA+ PD subjects, as an expected after-effect upon activation of CBS and rapid clearance of Hcy, as opposed to its accumulation in PD subjects with dementia. The gene discussed is CBS; the disease is Parkinson disease.